Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection.

Jillian Kallman PriceLynn H GerberMaria StepanovaLeyla de AvilaAli A WeinsteinHuong PhamFatema NaderMariam AfendyKathy TerraPatrick AustinWisna'odom KeoAndrei RacilaJames Michael EstepSuzannah GerberManisha VermaPegah GolabiBrian P LamZobair Younossi

Published in: International journal of general medicine (2023)

mAb treated participants had reduced symptom burden and consistently reported fewer symptoms than non-mAb at all time points despite less time since acute illness. Both groups reported a statistically significant decrease in symptoms by 6-month visit with no statistically significant differences between them at follow-up.

Keyphrases

liver failure
sars cov
respiratory failure
aortic dissection
drug induced
sleep quality
hepatitis b virus
monoclonal antibody
intensive care unit